Fatty liver disease used to be a problem of middle-aged alcoholics, but some lean people who drink little or no alcohol are also developing the condition. Non-alcoholic fatty liver disease predisposes patients to more severe illnesses, such as liver cancer or liver cirrhosis, which refers to the hardening and shrinkage of the organ. The first line of treatment is usually more exercise as prescribed by doctors. But new research from LKCMedicine may pave the way for better treatment of non-alcoholic fatty liver disease and its complications. The university's scientists have identified a protein in the liver that promotes the absorption and breakdown of lipids. If a drug could be developed to stimulate this protein in the liver, it could be another way for non-alcoholic fatty liver disease to be treated. he research was published in February this year in the science journal Gut, led by Professor of Metabolic Disease Walter Wahli. The findings, besides encouraging new drugs to be developed for the problem, could also pave the way for better use of existing medication, like fenofibrate, which stimulates PPAR-alpha activity, Prof Wahli added.